150 related articles for article (PubMed ID: 34034269)
1. Gastric cancer, inflammatory bowel disease and polyautoimmunity in a 17-year-old boy: CTLA-4 deficiency successfully treated with Abatacept.
Angelino G; Cifaldi C; Zangari P; Di Cesare S; Di Matteo G; Chiriaco M; Francalanci P; Faraci S; Rea F; Romeo EF; Amodio D; Ursu GM; Bertocchini A; Accinni A; Crocoli A; Inserra A; Cozza R; Romano C; Licciardello M; Rinelli M; Dall'Oglio L; Cancrini C; De Angelis P; Finocchi A
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1051-e1056. PubMed ID: 34034269
[TBL] [Abstract][Full Text] [Related]
2. Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
Mazzoni M; Dell'Orso G; Grossi A; Ceccherini I; Viola S; Terranova P; Micalizzi C; Guardo D; Massaccesi E; Palmisani E; Calvillo M; Fioredda F; Malattia C; Dufour C; Ravelli A; Miano M
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1168-e1172. PubMed ID: 33625086
[TBL] [Abstract][Full Text] [Related]
3. Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4.
Lee S; Moon JS; Lee CR; Kim HE; Baek SM; Hwang S; Kang GH; Seo JK; Shin CH; Kang HJ; Ko JS; Park SG; Choi M
J Allergy Clin Immunol; 2016 Jan; 137(1):327-330. PubMed ID: 26478010
[No Abstract] [Full Text] [Related]
4. Assessment of CTLA-4 Deficiency-Related Autoimmune Choroidopathy Response to Abatacept.
Shields CL; Say EA; Mashayekhi A; Garg SJ; Dunn JP; Shields JA
JAMA Ophthalmol; 2016 Jul; 134(7):844-6. PubMed ID: 27258812
[No Abstract] [Full Text] [Related]
5. Multiple Presentations of LRBA Deficiency: a Single-Center Experience.
Kostel Bal S; Haskologlu S; Serwas NK; Islamoglu C; Aytekin C; Kendirli T; Kuloglu Z; Yavuz G; Dalgic B; Siklar Z; Kansu A; Ensari A; Boztug K; Dogu F; Ikinciogullari A
J Clin Immunol; 2017 Nov; 37(8):790-800. PubMed ID: 28956255
[TBL] [Abstract][Full Text] [Related]
6. Abatacept is useful in autoimmune cytopenia with immunopathologic manifestations caused by CTLA-4 defects.
Dhunputh C; Ducassou S; Fernandes H; Picard C; Rieux-Laucat F; Viallard JF; Lazaro E; Hermine O; Jouvray M; Machelard I; Lambilliotte A; Malphettes M; Moshous D; Neven B; Gauthier A; Garnier N; Leblanc T; Landman-Parker J; Leverger G; Aladjidi N
Blood; 2022 Jan; 139(2):300-304. PubMed ID: 34714911
[No Abstract] [Full Text] [Related]
7. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
8. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic options for CTLA-4 insufficiency.
Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Refractory Autoimmune Gastritis Responsive to Abatacept in LRBA Deficiency.
Boz V; Valencic E; Girardelli M; Pin A; Gàmez-Diaz L; Tommasini A; Lega S; Bramuzzo M
Front Immunol; 2021; 12():619246. PubMed ID: 33717114
[TBL] [Abstract][Full Text] [Related]
11. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Intracerebral Lesions with Abatacept in a CTLA4-Haploinsufficient Patient.
van Leeuwen EM; Cuadrado E; Gerrits AM; Witteveen E; de Bree GJ
J Clin Immunol; 2018 May; 38(4):464-467. PubMed ID: 29796761
[No Abstract] [Full Text] [Related]
13. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency.
Taghizade N; Babayeva R; Kara A; Karakus IS; Catak MC; Bulutoglu A; Haskologlu ZS; Akay Haci I; Tunakan Dalgic C; Karabiber E; Bilgic Eltan S; Yorgun Altunbas M; Sefer AP; Sezer A; Kokcu Karadag SI; Arik E; Karali Z; Ozhan Kont A; Tuzer C; Karaman S; Mersin SS; Kasap N; Celik E; Kocacik Uygun DF; Aydemir S; Kiykim A; Aydogmus C; Ozek Yucel E; Celmeli F; Karatay E; Bozkurtlar E; Demir S; Metin A; Karaca NE; Kutukculer N; Aksu G; Guner SN; Keles S; Reisli I; Kendir Demirkol Y; Arikoglu T; Gulez N; Genel F; Kilic SS; Aytekin C; Keskin O; Yildiran A; Ozcan D; Altintas DU; Ardeniz FO; Dogu EF; Ikinciogullari KA; Karakoc-Aydiner E; Ozen A; Baris S
J Allergy Clin Immunol; 2023 Dec; 152(6):1634-1645. PubMed ID: 37595759
[TBL] [Abstract][Full Text] [Related]
14. Unusual Late-onset Enteropathy in a Patient With Lipopolysaccharide-responsive Beige-like Anchor Protein Deficiency.
Maggiore R; Grossi A; Fioredda F; Palmisani E; Terranova P; Cappelli E; Lanza T; Pierri F; Guardo D; Calvillo M; Micalizzi C; Beccaria A; Coccia MC; Arrigo S; Dufour C; Ceccherini I; Miano M
J Pediatr Hematol Oncol; 2020 Nov; 42(8):e768-e771. PubMed ID: 31876783
[TBL] [Abstract][Full Text] [Related]
15. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
16. Clinical, Radiologic, and Immunologic Features of Patients With CTLA4 Deficiency With Neurologic Involvement.
Coustal C; Goulabchand R; Labauge P; Guilpain P; Carra-Dallière C; Januel E; Jeziorski E; Salle V; Viallard JF; Boutboul D; Fieschi C; Gobert D; Aladjidi N; Rullier P; Graveleau J; Piel-Julian M; Suarez F; Neven B; Mahlaoui N; Ayrignac X
Neurology; 2023 Oct; 101(15):e1560-e1566. PubMed ID: 37487754
[TBL] [Abstract][Full Text] [Related]
17. Abatacept as a Long-Term Targeted Therapy for LRBA Deficiency.
Kiykim A; Ogulur I; Dursun E; Charbonnier LM; Nain E; Cekic S; Dogruel D; Karaca NE; Cogurlu MT; Bilir OA; Cansever M; Kapakli H; Baser D; Kasap N; Kutlug S; Altintas DU; Al-Shaibi A; Agrebi N; Kara M; Guven A; Somer A; Aydogmus C; Ayaz NA; Metin A; Aydogan M; Uncuoglu A; Patiroglu T; Yildiran A; Guner SN; Keles S; Reisli I; Aksu G; Kutukculer N; Kilic SS; Yilmaz M; Karakoc-Aydiner E; Lo B; Ozen A; Chatila TA; Baris S
J Allergy Clin Immunol Pract; 2019; 7(8):2790-2800.e15. PubMed ID: 31238161
[TBL] [Abstract][Full Text] [Related]
18. CTLA-4: From mechanism to autoimmune therapy.
Hosseini A; Gharibi T; Marofi F; Babaloo Z; Baradaran B
Int Immunopharmacol; 2020 Mar; 80():106221. PubMed ID: 32007707
[TBL] [Abstract][Full Text] [Related]
19. A Patient with CTLA-4 Haploinsufficiency Presenting Gastric Cancer.
Hayakawa S; Okada S; Tsumura M; Sakata S; Ueno Y; Imai K; Morio T; Ohara O; Chayama K; Kobayashi M
J Clin Immunol; 2016 Jan; 36(1):28-32. PubMed ID: 26644313
[TBL] [Abstract][Full Text] [Related]
20. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
